SPRO: Spero Therapeutics, Inc. Quarterly EPS earnings growth

Public company logo of Spero Therapeutics (SPRO)

Spero Therapeutics (SPRO) develops innovative antibiotics to combat superbugs, which drives short-term market interest. However, long-term success depends on regulatory approvals and hospital contracts. This chart from GURU.Markets links the quarterly EPS growth to seamless logistics via specialized networks, while the -478.90 level captures the latest values of the issuer's fundamental condition.

Spero Therapeutics Inc (SPRO) - Year-over-year net earnings per share growth for the last 12 months from 07/04/2022 to 11/14/2026

Summary analytical data breakdowns for Spero Pharma (SPRO)

- share price and expert price forecast:
Stock Price Spero Therapeutics, Inc.|SPRO - Forecast Levels Chart
- market capitalization information:
Market Capitalization Spero|SPRO - Total Enterprise Value
- balance sheet net asset value indicators:
Book Value per Share Spero Therapeutics|SPRO - Company Net Assets|Market Cap to Net Assets Ratio sperotherapeutics.com|SPRO - Aggregate Business Assets
- company liabilities and liquidity data:
Total Debt to Capital Spero Therapeutics|SPRO - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Spero Therapeutics|SPRO - Company Cumulative Debt|Debt to Book Capitalization Ratio Spero|SPRO - Company Long-Term Indebtedness|Company Short-Term Debt Spero Therapeutics|Quick Liquidity sperotherapeutics.com
- earnings and valuation multiples indicators:
SPRO - Net Financial Result|Expected Profit Spero Therapeutics|SPRO - Market Cap to Net Income|Forward P/E Multiple Spero|SPRO - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Spero|SPRO - Income before deduction of interest, taxes and amortization|Earnings per share for the last twelve months Spero Therapeutics|SPRO - Net earnings per one share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months sperotherapeutics.com|SPRO - Earnings per share increase in current year|Expected earnings per share growth for next year Spero Therapeutics
- revenue and sales proceeds data:
SPRO - Company Total Sales|Projected Sales Volume Spero Therapeutics, Inc.|SPRO - Market Capitalization-to-Revenue Ratio|Forward P/S Multiple Spero
Comprehensive company analysis:Spero Therapeutics
Flagship merchandise of Spero Therapeutics

To decouple fundamental value from market speculation, it is critical to analyze quarterly EPS dynamics, which measure the rate of change in net income per share and reveal the impact of operating expenses on profitability. At Spero Therapeutics (SPRO), strict treasury controls and transparent partnerships minimize cash burn, allowing this chart to assess the business's actual resilience to inflationary pressure.

Key competitors

SMMT: Quarterly EPS earnings growth|Year-over-year net earnings per share trend for the last twelve months MRNA (Moderna Inc)|PCVX (Vaxcyte Corp) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Tarsus Corp TARS|Quarterly EPS earnings growth CRMD|Year-over-year net earnings per share growth for the last 12 months serestherapeutics.com MCRB|SCYNEXIS - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months ANTX (AN2 Therapeutics Inc)|PolyPid Limited - Quarterly EPS earnings growth|Year-over-year net earnings per share change for the last twelve months YS Biopharma Co., Ltd. LSB|iterumtx.com (ITRM) - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months BiomX (PHGE)|Year-over-year earnings per share growth for the last twelve months Soligenix Inc|Year-over-year earnings per share growth for the last 12 months SXTP (60 Degrees Pharma)|Year-over-year earnings per share growth for the last twelve months Oragenics, Inc. (OGEN)|Year-over-year net earnings per share change for the last twelve months OpGen Corporation